Johannes Liese
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Johannes Liese has a total of 357 co-authors. Here are the top co-authors by number of shared publications:
- Andrea Streng
Department of Pediatrics, University Hospital Würzburg, Würzburg, Germany
17 shared publications - Ulrich Heininger
University of Basel Children’s Hospital , Basel
12 shared publications - Johannes Forster9 shared publications
- Arne Simon
Pediatric Oncology and Hematology, University Hospital Homburg Saar, Homburg/Saar, Germany
8 shared publications Johannes Forster
Merzhausen, Deutschland
8 shared publications- Reinhard Berner
Department of Pediatrics, University Hospital and Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
8 shared publications
Latest Publications
- Open Access
- 9 November 2026
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 185 (12) , 925
Clinical recommendations for the inpatient management of lower respiratory tract infections in children and adolescents with severe neurological impairment in Germany—2026 Update
Children and adolescents with severe neurological impairment (SNI) require specialized care due to their complex medical needs. These patients often experience severe, recurrent lower respiratory tract infections (LRTIs). These infections, of both viral and bacterial etiology, pose a significant risk to these patients, often resulting in respiratory insufficiency and long-term impairments. Based on expert consensus and newly available data, we have updated the previous 2024 clinical recommendations on the management of LRTIs in children and adolescents with SNI in Germany. This update now also addresses multidrug-resistant organism colonization, respiratory support, discharge planning, and prophylactic strategies. The recommendations emphasize comprehensive multidisciplinary care, antimicrobial stewardship, and a stepwise, risk-stratified approach to antibiotic therapy. Initial treatment should involve symptomatic care, including hydration, antipyretics, oxygen therapy, secretion management, and respiratory as well as cough support. In suspected bacterial LRTIs, antibiotic treatment (ABT) should be guided by clinical severity, previous microbiological findings, and treatment response, with an aminopenicillin plus a beta-lactamase inhibitor recommended for community-acquired LRTIs and piperacillin-tazobactam reserved for selected high-risk patients. Ongoing management includes regular reassessment, adjustment of ABT based on pathogen identification, and optimization of supportive care. Conclusion : The updated recommendations provide a practical, multidisciplinary framework for the inpatient management of LRTIs in children and adolescents with SNI, combining optimized supportive care with antimicrobial stewardship and a stepwise, risk-stratified approach to antibiotic treatment. What is Known: • Children and adolescents with severe neurological impairment are particularly affected by severe and recurrent lower respiratory tract infections (LRTI) • The indication and choice of antibiotic therapy for bacterial LRTI is often difficult because there are no evidence-based treatment recommendations for this heterogeneous but vulnerable patient population • The frequent overuse of broad-spectrum or reserve antibiotics in this patient population increases selection pressure for multidrug-resistant pathogens What is New: • Compared with the 2024 recommendations, this update provides more detailed guidance on secretion management and respiratory and cough support, introduces explicit discharge criteria, and expands decision-making for patients colonized with multidrug-resistant organisms. The antibiotic strategy has been further specified regarding broad-spectrum antibiotic therapy, while preventive recommendations have been expanded and updated.
- 9 November 2026
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 185 (12) , 925
Open AccessClinical recommendations for the inpatient management of lower respiratory tract infections in children and adolescents with severe neurological impairment in Germany—2026 Update
Children and adolescents with severe neurological impairment (SNI) require specialized care due to their complex medical needs. These patients often experience severe, recurrent lower respiratory tract infections (LRTIs). These infections, of both viral and bacterial etiology, pose a significant risk to these patients, often resulting in respiratory insufficiency and long-term impairments. Based on expert consensus and newly available data, we have updated the previous 2024 clinical recommendations on the management of LRTIs in children and adolescents with SNI in Germany. This update now also addresses multidrug-resistant organism colonization, respiratory support, discharge planning, and prophylactic strategies. The recommendations emphasize comprehensive multidisciplinary care, antimicrobial stewardship, and a stepwise, risk-stratified approach to antibiotic therapy. Initial treatment should involve symptomatic care, including hydration, antipyretics, oxygen therapy, secretion management, and respiratory as well as cough support. In suspected bacterial LRTIs, antibiotic treatment (ABT) should be guided by clinical severity, previous microbiological findings, and treatment response, with an aminopenicillin plus a beta-lactamase inhibitor recommended for community-acquired LRTIs and piperacillin-tazobactam reserved for selected high-risk patients. Ongoing management includes regular reassessment, adjustment of ABT based on pathogen identification, and optimization of supportive care. Conclusion : The updated recommendations provide a practical, multidisciplinary framework for the inpatient management of LRTIs in children and adolescents with SNI, combining optimized supportive care with antimicrobial stewardship and a stepwise, risk-stratified approach to antibiotic treatment. What is Known: • Children and adolescents with severe neurological impairment are particularly affected by severe and recurrent lower respiratory tract infections (LRTI) • The indication and choice of antibiotic therapy for bacterial LRTI is often difficult because there are no evidence-based treatment recommendations for this heterogeneous but vulnerable patient population • The frequent overuse of broad-spectrum or reserve antibiotics in this patient population increases selection pressure for multidrug-resistant pathogens What is New: • Compared with the 2024 recommendations, this update provides more detailed guidance on secretion management and respiratory and cough support, introduces explicit discharge criteria, and expands decision-making for patients colonized with multidrug-resistant organisms. The antibiotic strategy has been further specified regarding broad-spectrum antibiotic therapy, while preventive recommendations have been expanded and updated.
- 3 November 2026
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
Predictors of Antibiotic Overuse in Febrile Children
Background: Antibiotic overuse contributes to antimicrobial resistance. Mechanisms that drive overuse, including diagnostic uncertainty, are thought to be complex. We aimed to investigate predictive factors for antibiotic overuse in a large pediatric cohort. Methods: This is a subanalysis from the AutoPilot-Dx study, which enrolled febrile children 90 days to 18 years old presenting to the pediatric emergency department with respiratory tract infection or fever without source, including both hospitalized children and those discharged home. We analyzed patient flow from being treated with antibiotics at recruitment to definitive antibiotic treatment after assessment, depending on physician judgment. Variables significantly associated with antibiotic overuse in univariate analysis were entered into a multivariable logistic regression model to identify independent predictors of antibiotic overuse, defined as receipt of antibiotic treatment following clinical assessment in cases with viral panel-adjudicated diagnosis. Diagnostic uncertainty was assessed by treating physicians. Results: Upon recruitment, 127/1008 (12.6%) were receiving antibiotic treatment. Overall, 186 of 628 cases with a viral panel-adjudicated diagnosis were judged to have antibiotic overuse. Factors with significant association in univariate analysis were diagnostic uncertainty, nonexudative tonsillitis, rales and younger age. Presence of a diagnostic test result upon presentation to the hospital and current antibiotic treatment were found not to be associated with overuse. Among 566 of 1008 cases with complete data on all model covariates, multivariable logistic regression yielded diagnostic uncertainty [odds ratio (OR), 2.09; 95% confidence interval (CI): 1.18–3.93; P = 0.015], nonexudative tonsillitis (OR, 2.78; 95% CI: 1.72–4.59; P < 0.001) and rales (OR, 1.82; 95% CI: 1.15–2.86; P = 0.01) to be positively associated with antibiotic overuse, while age showed a negative association in complete-case analysis (OR, 0.93; 95% CI: 0.85–0.99; P = 0.038), which attenuated and was no longer significant in a multiple imputation sensitivity analysis (OR, 0.96; 95% CI: 0.91–1.01; P = 0.150). Conclusions: Diagnostic uncertainty contributes to antibiotic overuse, alongside clinical factors. Future studies should investigate the impact of improved diagnostic algorithms on antibiotic prescribing in patients with respiratory tract infections in whom physicians experience diagnostic uncertainty.
- 3 November 2026
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
Predictors of Antibiotic Overuse in Febrile Children
Background: Antibiotic overuse contributes to antimicrobial resistance. Mechanisms that drive overuse, including diagnostic uncertainty, are thought to be complex. We aimed to investigate predictive factors for antibiotic overuse in a large pediatric cohort. Methods: This is a subanalysis from the AutoPilot-Dx study, which enrolled febrile children 90 days to 18 years old presenting to the pediatric emergency department with respiratory tract infection or fever without source, including both hospitalized children and those discharged home. We analyzed patient flow from being treated with antibiotics at recruitment to definitive antibiotic treatment after assessment, depending on physician judgment. Variables significantly associated with antibiotic overuse in univariate analysis were entered into a multivariable logistic regression model to identify independent predictors of antibiotic overuse, defined as receipt of antibiotic treatment following clinical assessment in cases with viral panel-adjudicated diagnosis. Diagnostic uncertainty was assessed by treating physicians. Results: Upon recruitment, 127/1008 (12.6%) were receiving antibiotic treatment. Overall, 186 of 628 cases with a viral panel-adjudicated diagnosis were judged to have antibiotic overuse. Factors with significant association in univariate analysis were diagnostic uncertainty, nonexudative tonsillitis, rales and younger age. Presence of a diagnostic test result upon presentation to the hospital and current antibiotic treatment were found not to be associated with overuse. Among 566 of 1008 cases with complete data on all model covariates, multivariable logistic regression yielded diagnostic uncertainty [odds ratio (OR), 2.09; 95% confidence interval (CI): 1.18–3.93; P = 0.015], nonexudative tonsillitis (OR, 2.78; 95% CI: 1.72–4.59; P < 0.001) and rales (OR, 1.82; 95% CI: 1.15–2.86; P = 0.01) to be positively associated with antibiotic overuse, while age showed a negative association in complete-case analysis (OR, 0.93; 95% CI: 0.85–0.99; P = 0.038), which attenuated and was no longer significant in a multiple imputation sensitivity analysis (OR, 0.96; 95% CI: 0.91–1.01; P = 0.150). Conclusions: Diagnostic uncertainty contributes to antibiotic overuse, alongside clinical factors. Future studies should investigate the impact of improved diagnostic algorithms on antibiotic prescribing in patients with respiratory tract infections in whom physicians experience diagnostic uncertainty.
- Open Access
- 10 April 2026
- Published by Springer Nature in Molecular and Cellular Pediatrics
- Vol. 13 (1) , 14
Risk factors and outcomes of delayed completion of the hexavalent 3 + 1 immunisation series in German preterm infants – an observational study
Background: Although very low birthweight infants (VLBWI, birthweight < 1500 g) are at increased risk of infectious diseases, they frequently receive primary vaccinations with the hexavalent vaccine (DTaP-IPV-Hib-HepB) later than recommended. Detailed data on the adherence to the hexavalent 3 + 1 immunisation schedule (at 2, 3, 4 and 11 months of age) in German VLBWI are scarce. Objective: This study evaluated the timeliness of the primary hexavalent vaccination series among VLBWI from the German Neonatal Network (GNN) and aimed at identifying risk factors and outcomes associated with delayed series completion. Study design and methods: As part of the multicentre, population-based GNN, N = 3,394 VLBWI born between 2009 and 2016 underwent a follow-up examination at 6 years of age, including documentation of vaccination certificates. Uni- and multivariate analyses were performed to evaluate the timely completion of the 3 + 1 schedule for hexavalent immunisation and to examine risk factors and outcomes associated with delays. Results: Despite a high overall hexavalent vaccination coverage of more than 97% by six years of age, only 3.3% ( n = 108) of VLBWI received the hexavalent booster at the recommended age of 11 months, and 41.6% ( n = 1,373) had completed the primary vaccination series by 15 months of age. Progressive delays were observed across subsequent doses, with the lowest schedule-adherent coverage recorded for the booster dose. A timely first hexavalent vaccination (OR 0.61; 95% CI 0.52–0.72) was protective against delayed series completion, while bronchopulmonary dysplasia (BPD) was associated with a delay of the booster beyond 15 months of age (OR 1.31; 95% CI 1.07–1.61). Timely series completion was associated with decreased risk of incomplete vaccine protection at daycare entry (OR 0.09; 95% CI 0.07–0.14) and a lower rate of parent-reported pertussis within the first 6 years of life (OR 0.47; 95% CI 0.24–0.90). Conclusion: Our data demonstrate significant delays in the primary vaccination series which were most pronounced at the booster dose and particularly affects the most susceptible infants, i.e., VLBWI with BPD. However, vulnerable preterm infants would benefit greatly from timely vaccinations to ensure optimal protection by the time they are increasingly exposed to infectious pathogens, as for instance upon entry into childcare settings.
- 10 April 2026
- Published by Springer Nature in Molecular and Cellular Pediatrics
- Vol. 13 (1) , 14
Open AccessRisk factors and outcomes of delayed completion of the hexavalent 3 + 1 immunisation series in German preterm infants – an observational study
Background: Although very low birthweight infants (VLBWI, birthweight < 1500 g) are at increased risk of infectious diseases, they frequently receive primary vaccinations with the hexavalent vaccine (DTaP-IPV-Hib-HepB) later than recommended. Detailed data on the adherence to the hexavalent 3 + 1 immunisation schedule (at 2, 3, 4 and 11 months of age) in German VLBWI are scarce. Objective: This study evaluated the timeliness of the primary hexavalent vaccination series among VLBWI from the German Neonatal Network (GNN) and aimed at identifying risk factors and outcomes associated with delayed series completion. Study design and methods: As part of the multicentre, population-based GNN, N = 3,394 VLBWI born between 2009 and 2016 underwent a follow-up examination at 6 years of age, including documentation of vaccination certificates. Uni- and multivariate analyses were performed to evaluate the timely completion of the 3 + 1 schedule for hexavalent immunisation and to examine risk factors and outcomes associated with delays. Results: Despite a high overall hexavalent vaccination coverage of more than 97% by six years of age, only 3.3% ( n = 108) of VLBWI received the hexavalent booster at the recommended age of 11 months, and 41.6% ( n = 1,373) had completed the primary vaccination series by 15 months of age. Progressive delays were observed across subsequent doses, with the lowest schedule-adherent coverage recorded for the booster dose. A timely first hexavalent vaccination (OR 0.61; 95% CI 0.52–0.72) was protective against delayed series completion, while bronchopulmonary dysplasia (BPD) was associated with a delay of the booster beyond 15 months of age (OR 1.31; 95% CI 1.07–1.61). Timely series completion was associated with decreased risk of incomplete vaccine protection at daycare entry (OR 0.09; 95% CI 0.07–0.14) and a lower rate of parent-reported pertussis within the first 6 years of life (OR 0.47; 95% CI 0.24–0.90). Conclusion: Our data demonstrate significant delays in the primary vaccination series which were most pronounced at the booster dose and particularly affects the most susceptible infants, i.e., VLBWI with BPD. However, vulnerable preterm infants would benefit greatly from timely vaccinations to ensure optimal protection by the time they are increasingly exposed to infectious pathogens, as for instance upon entry into childcare settings.
- 1 January 2026
- Published by Georg Thieme Verlag KG
Varizellen- und Zoster-Infektionen
- 1 January 2026
- Published by Georg Thieme Verlag KG
Infektiologische Grundbegriffe Infektiologie
- 1 January 2026
- Published by Georg Thieme Verlag KG
Influenza Influenza
- 1 January 2026
- Published by Georg Thieme Verlag KG
Bronchiolitis
- 1 January 2026
- Published by Georg Thieme Verlag KG
Pneumonie
- 1 January 2026
- Published by Georg Thieme Verlag KG
Pneumokokken-Infektionen